SOUTHPORT, CT--(Marketwired - Oct 15, 2015) -  Thetis Pharmaceuticals, LLC ("Thetis"), a privately-held biopharmaceutical company, today announced that it will be presenting at the 14th Annual BIO Investor Forum at the Parc 55 San Francisco at 11 am on October 20, 2015 in the Balboa Room. The presentation will focus on two pipeline candidates, TP-252 and TP-452, which Thetis plans to advance into clinical development in 2016.

TP-252 is a novel derivative of eicosapentaenoic acid (EPA) for use as adjunct therapy to endoscopic surveillance for the treatment of familial adenomatous polyposis (FAP). This rare disease is a dominantly inherited condition resulting in formation of numerous large colon polyps in late childhood or adolescence. If left untreated, patients inevitably develop colorectal cancer by middle age. There are no drugs currently marketed for the treatment of this condition. The demonstrated efficacy of EPA-FFA in reducing polyp burden, coupled with its favorable safety profile, suggests TP-252 has good prospects for chronic use in this peri-pediatric patient population. 

TP-452, a novel derivative of docosapentaenoic acid (DPA), has potential as adjunct therapy to statins for oral treatment of elevated LDL cholesterol (LDL-C). Nearly 79 million adults in the United States have high LDL-C, and approximately 27 million are treated with statins, the standard of care for this condition. Despite treatment, nine million statin users still have uncontrolled LDL-C. Laboratory findings suggest that DPA could exert unique synergistic anti-hyperlipidemic effects in combination with statins. Further, preclinical and clinical observations indicate that DPA down-regulates both HMGCoA reductase and PCSK-9. Through these dual pharmacological actions, DPA has prospects for reducing cholesterol biosynthesis and increasing LDL receptor levels. Based on these data, TP-452 offers attractive credentials as a highly differentiated therapeutic agent for reduction of LDL-C in patients not at treatment goal.

About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a privately held biopharmaceutical company applying its expertise in amino-lipid chemistry to discover and develop innovative drugs for the treatment of cardiometabolic and gastrointestinal diseases. Thetis uses its proprietary HEALER platform to transform approved drugs or previously studied biologically active agents into new chemical entities with better pharmacokinetic, pharmacodynamic or physico-chemical properties, thereby enhancing their efficacy, tolerability and patient convenience. This approach enables the development of known agents for new, previously unattainable indications and offers an approach to drug discovery and clinical development that is potentially more efficient and less expensive than conventional small molecule drug research and development. Thetis is implementing this approach to develop a robust pipeline of potential new medicines targeting major and rare diseases.

Contact Information:

Name: Michelle Linn
Phone: Number 774-696-3803
Email Address: